W James Morris1, Scott Tyldesley2, Sree Rodda3, Ross Halperin4, Howard Pai5, Michael McKenzie2, Graeme Duncan2, Gerard Morton6, Jeremy Hamm7, Nevin Murray8. 1. Department of Surgery, University of British Columbia, Vancouver, British Columbia, Canada; BC Cancer Agency-Vancouver Centre, Vancouver, British Columbia, Canada. Electronic address: jmorris@bccancer.bc.ca. 2. Department of Surgery, University of British Columbia, Vancouver, British Columbia, Canada; BC Cancer Agency-Vancouver Centre, Vancouver, British Columbia, Canada. 3. Department of Surgery, University of British Columbia, Vancouver, British Columbia, Canada. 4. Department of Surgery, University of British Columbia, Vancouver, British Columbia, Canada; BC Cancer Agency-Centre for the Southern Interior, Vancouver, British Columbia, Canada. 5. Department of Surgery, University of British Columbia, Vancouver, British Columbia, Canada; BC Cancer Agency-Vancouver Island Centre, Vancouver, British Columbia, Canada. 6. Department of Radiation Oncology, University of Toronto, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. 7. Department of Population Oncology, BC Cancer Agency, Vancouver, British Columbia, Canada. 8. BC Cancer Agency-Vancouver Centre, Vancouver, British Columbia, Canada; Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Abstract
PURPOSE: To report the primary endpoint of biochemical progression-free survival (b-PFS) and secondary survival endpoints from ASCENDE-RT, a randomized trial comparing 2 methods of dose escalation for intermediate- and high-risk prostate cancer. METHODS AND MATERIALS: ASCENDE-RT enrolled 398 men, with a median age of 68 years; 69% (n=276) had high-risk disease. After stratification by risk group, the subjects were randomized to a standard arm with 12 months of androgen deprivation therapy, pelvic irradiation to 46 Gy, followed by a dose-escalated external beam radiation therapy (DE-EBRT) boost to 78 Gy, or an experimental arm that substituted a low-dose-rate prostate brachytherapy (LDR-PB) boost. Of the 398 trial subjects, 200 were assigned toDE-EBRT boost and 198 to LDR-PB boost. The median follow-up was 6.5 years. RESULTS: In an intent-to-treat analysis, men randomized to DE-EBRT were twice as likely to experience biochemical failure (multivariable analysis [MVA] hazard ratio [HR] 2.04; P=.004). The 5-, 7-, and 9-year Kaplan-Meier b-PFS estimates were 89%, 86%, and 83% for the LDR-PB boost versus 84%, 75%, and 62% for the DE-EBRT boost (log-rank P<.001). The LDR-PB boost benefited both intermediate- and high-risk patients. Because the b-PFS curves for the treatment arms diverge sharply after 4 years, the relative advantage of the LDR-PB should increase with longer follow-up. On MVA, the only variables correlated with reduced overall survival were age (MVA HR 1.06/y; P=.004) and biochemical failure (MVA HR 6.30; P<.001). Although biochemical failure was associated with increased mortality and randomization to DE-EBRT doubled the rate of biochemical failure, no significant overall survival difference was observed between the treatment arms (MVA HR 1.13; P=.62). CONCLUSIONS: Compared with 78 Gy EBRT, men randomized to the LDR-PB boost were twice as likely to be free of biochemical failure at a median follow-up of 6.5 years.
RCT Entities:
PURPOSE: To report the primary endpoint of biochemical progression-free survival (b-PFS) and secondary survival endpoints from ASCENDE-RT, a randomized trial comparing 2 methods of dose escalation for intermediate- and high-risk prostate cancer. METHODS AND MATERIALS: ASCENDE-RT enrolled 398 men, with a median age of 68 years; 69% (n=276) had high-risk disease. After stratification by risk group, the subjects were randomized to a standard arm with 12 months of androgen deprivation therapy, pelvic irradiation to 46 Gy, followed by a dose-escalated external beam radiation therapy (DE-EBRT) boost to 78 Gy, or an experimental arm that substituted a low-dose-rate prostate brachytherapy (LDR-PB) boost. Of the 398 trial subjects, 200 were assigned to DE-EBRT boost and 198 to LDR-PB boost. The median follow-up was 6.5 years. RESULTS: In an intent-to-treat analysis, men randomized to DE-EBRT were twice as likely to experience biochemical failure (multivariable analysis [MVA] hazard ratio [HR] 2.04; P=.004). The 5-, 7-, and 9-year Kaplan-Meier b-PFS estimates were 89%, 86%, and 83% for the LDR-PB boost versus 84%, 75%, and 62% for the DE-EBRT boost (log-rank P<.001). The LDR-PB boost benefited both intermediate- and high-risk patients. Because the b-PFS curves for the treatment arms diverge sharply after 4 years, the relative advantage of the LDR-PB should increase with longer follow-up. On MVA, the only variables correlated with reduced overall survival were age (MVA HR 1.06/y; P=.004) and biochemical failure (MVA HR 6.30; P<.001). Although biochemical failure was associated with increased mortality and randomization to DE-EBRT doubled the rate of biochemical failure, no significant overall survival difference was observed between the treatment arms (MVA HR 1.13; P=.62). CONCLUSIONS: Compared with 78 Gy EBRT, men randomized to the LDR-PB boost were twice as likely to be free of biochemical failure at a median follow-up of 6.5 years.
Authors: Marigdalia K Ramirez-Fort; Marc J Rogers; Roberto Santiago; Sean S Mahase; Melissa Mendez; Yi Zheng; Xiang Kong; James A Kashanian; M Junaid Niaz; Shearwood McClelland; Xiaodong Wu; Neil H Bander; Peter Schlegel; John P Mulhall; Christopher S Lange Journal: Rep Pract Oncol Radiother Date: 2020-03-19
Authors: Anna Rita Alitto; Luca Tagliaferri; Valentina Lancellotta; Andrea D'Aviero; Antonio Piras; Vincenzo Frascino; Francesco Catucci; Bruno Fionda; Christian Staackmann; Simonetta Saldi; Vincenzo Valentini; Gyorgy Kovacs; Cynthia Aristei; Giovanna Mantini Journal: In Vivo Date: 2020 May-Jun Impact factor: 2.155
Authors: Mira Keyes; Juanita Crook; W James Morris; Gerard Morton; Tom Pickles; Nawaid Usmani; Eric Vigneault Journal: Can Urol Assoc J Date: 2013 Jan-Feb Impact factor: 1.862
Authors: Adam Ferro; Hee Joon Bae; Gayane Yenokyan; Yi Le; Todd McNutt; Omar Mian; Carol Gergis; Chloe Haviland; Theodore L DeWeese; Daniel Y Song Journal: Brachytherapy Date: 2017-11-23 Impact factor: 2.362
Authors: Jeff M Michalski; Jennifer Moughan; James Purdy; Walter Bosch; Deborah W Bruner; Jean-Paul Bahary; Harold Lau; Marie Duclos; Matthew Parliament; Gerard Morton; Daniel Hamstra; Michael Seider; Michael I Lock; Malti Patel; Hiram Gay; Eric Vigneault; Kathryn Winter; Howard Sandler Journal: JAMA Oncol Date: 2018-06-14 Impact factor: 31.777
Authors: Radka Stoyanova; Felix Chinea; Deukwoo Kwon; Isildinha M Reis; Yohann Tschudi; Nestor A Parra; Adrian L Breto; Kyle R Padgett; Alan Dal Pra; Matthew C Abramowitz; Oleksandr N Kryvenko; Sanoj Punnen; Alan Pollack Journal: Int J Radiat Oncol Biol Phys Date: 2018-06-13 Impact factor: 7.038
Authors: Daniel A Hamstra; Stephanie L Pugh; Herbert Lepor; Seth A Rosenthal; Kenneth J Pienta; Leonard Gomella; Christopher Peters; David Paul D'Souza; Kenneth L Zeitzer; Christopher U Jones; William A Hall; Eric Horwitz; Thomas M Pisansky; Luis Souhami; Alan C Hartford; Michael Dominello; Felix Feng; Howard M Sandler Journal: Radiother Oncol Date: 2019-09-17 Impact factor: 6.280